The VIP study was a multicentre, prospective, case-control study, investigating whether immunosuppressive treatments reduced antibody and T-cell responses in patients with inflammatory bowel disease (IBD) after a third COVID-19 vaccine dose. In this touchIMMUNOLOGY interview, we speak with Dr. James Alexander (Imperial College London, London, UK) to discuss the aims, methodology and findings from the VIP study.
The abstract entitled ‘COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE’ (Abstract no: LB15) was presented at UEG Week, October 8 – 11, 2022.
- Why is it important for immunosuppressed patients to be prioritised for booster doses of the COVID vaccine? (0:16)
- What was previously known about the effect of immunosuppressive treatments on antibody and T-cell responses in patients with inflammatory bowel disease (IBD)? (0:58)
- What were the aims and methodology of the VIP study? (1:59)
- What immunosuppressive treatments had an impact on antibody and T-cell responses after a third vaccine dose? (3:26)
- What impact will these findings have on vaccine booster dosing? (4:49)
Disclosures: James Alexander has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!